Hormone receptor positive HER2 negative breast cancer
Not recruitingA Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment
A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:AbemaciclibAnastrozole+8
Poland- Participants:18–64 years · 65+ years
- Substances:Abemaciclib
- Sponsor:AstraZeneca AB














